CULLINAN THERAPEUTICS INC. - COMMON STOCK
12.69
25-November-24 13:11:59
15 minutes delayed
Stocks
+0.15
+1.20%
Today's range
12.33 - 13.02
ISIN
N/A
Source
NASDAQ
-
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
26 May 2022 08:45:00 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
19 May 2022 08:00:01 By Nasdaq GlobeNewswire
-
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
16 May 2022 06:45:00 By Nasdaq GlobeNewswire
-
12 May 2022 02:00:00 By Nasdaq GlobeNewswire
-
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2022 17:10:24 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
05 Apr 2022 08:00:01 By Nasdaq GlobeNewswire
-
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2022 16:34:22 By Nasdaq GlobeNewswire
-
28 Mar 2022 16:01:00 By Nasdaq GlobeNewswire
-
17 Mar 2022 07:08:06 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
09 Mar 2022 08:00:02 By Nasdaq GlobeNewswire
-
08 Mar 2022 17:30:00 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference
07 Feb 2022 06:30:00 By Nasdaq GlobeNewswire
-
10 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
05 Jan 2022 09:00:02 By Nasdaq GlobeNewswire
-
04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire
-
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16 Dec 2021 06:30:00 By Nasdaq GlobeNewswire
-
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13 Dec 2021 07:00:00 By Nasdaq GlobeNewswire